Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...
The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...
Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments ...
Pharmaceutical Technology on MSN11d
Latigo secures $150m for non-opioid pain treatment developmentLatigo Biotherapeutics has secured $150m in a Series B financing round, which will be used to further the development of its ...
If it wasn't obvious before, Latigo Biotherapeutics is all in on its non-opioid pain treatment pipeline and that is highlighted further by the company's $150 million Series B capital raise. Announced ...
Latigo Biotherapeutics, Vivace Therapeutics, and Vori Health each announced the recent successful closing of their respective ...
Latigo Biotherapeutics has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, ...
The Food and Drug Administration has granted Fast Track designation to LTG-001 for the treatment of acute pain.
Big raises slowed for the second week in a row. Only a handful of rounds hit nine digits this week, although a large ...
Latigo Biotherapeutics has secured $150m in a Series B financing round, which will be used to further the development of its Na v 1.8 inhibitors, which are being developed as non-opioid treatments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback